
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.






